title: Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction.
abstract: BACKGROUND
  Prior studies have yielded conflicting data on the advantage of primary angioplasty compared with thrombolysis in elderly patients with acute myocardial infarction (AMI). These studies, however, were performed before the contemporary widespread use of intracoronary stents and glycoprotien IIb/IIIa antagonists.
  
  
  METHODS
  We prospectively compared the outcome of 130 consecutive elderly patients (aged > or =70 years) with ST-elevation AMI who were admitted to 2 similar neighboring medical centers. Patients were assigned to receive either thrombolytic therapy with accelerated tissue-type plasminogen activator (center I) or primary angioplasty with routine stenting (center II).
  
  
  RESULTS
  Of the patients assigned to receive primary angioplasty, 91% underwent stenting. At 6 months, patients treated with primary angioplasty, compared with those treated with thrombolytic therapy, had a lower incidence of reinfarction (2% vs 14%, P =.053) and revascularization for recurrent ischemia (9% vs 61%, P <.001) and a significant reduction in the prespecified combined end point of death, reinfarction, or revascularization for recurrent ischemia (29% vs 93%, P <.01). Primary angioplasty remained an independent predictor of the triple combined end point after controlling for potential covariables (relative risk 0.63, 95% CI 0.38-0.84). Major bleeding complications were also significantly reduced in the primary angioplasty group (0% vs 17%, P =.03).
  
  
  CONCLUSIONS
  Compared with thrombolysis, primary angioplasty with routine stenting in elderly patients with AMI is associated with better clinical outcomes and a lower risk of bleeding complications.
authors.affiliation: Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: Ilan
authors.initials: I
authors.lastname: Goldenberg
authors.forename: Shlomi
authors.initials: S
authors.lastname: Matetzky
authors.forename: Amir
authors.initials: A
authors.lastname: Halkin
authors.forename: Arie
authors.initials: A
authors.lastname: Roth
authors.forename: Elio
authors.initials: E
authors.lastname: Di Segni
authors.forename: Dov
authors.initials: D
authors.lastname: Freimark
authors.forename: Dan
authors.initials: D
authors.lastname: Elian
authors.forename: Oren
authors.initials: O
authors.lastname: Agranat
authors.forename: Yedael
authors.initials: Y
authors.lastname: Har Zahav
authors.forename: Victor
authors.initials: V
authors.lastname: Guetta
authors.forename: Hanoch
authors.initials: H
authors.lastname: Hod
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D017052:Hospital Mortality; D006801:Humans; D007557:Israel / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D017202:Myocardial Ischemia / Q000209:etiology; D011446:Prospective Studies; D012008:Recurrence; D015607:Stents; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator